Therapy failure following selection of enfuvirtide-resistant HIV-1 in cerebrospinal fluid.
We report the selection of enfuvirtide-resistant human immunodeficiency virus type 1 in cerebrospinal fluid, resulting in subsequent loss of viral suppression in the plasma. This case report emphasizes the potential danger of low-level penetration of entry inhibitors into the central nervous system.
van Lelyveld
S F L
SF
Department of Virology, University Medical Center Utrecht, G04.614 Heidelberglaan 100, 3584 CX Utrecht, the Netherlands.
Nijhuis
M
M
Baatz
F
F
Wilting
I
I
van den Bergh
W M
WM
Kurowski
M
M
de Jong
D
D
Hoepelman
A I M
AI
Wensing
A M J
AM
D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002555:Cerebrospinal Fluid / Q000821:virology*; D024882:Drug Resistance, Viral; D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41 / Q000494:pharmacology* / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000494:pharmacology* / Q000627:therapeutic use; D012641:Selection, Genetic; D017211:Treatment Failure
D019380:Anti-HIV Agents; D015700:HIV Envelope Protein gp41; D010446:Peptide Fragments; D000077560:Enfuvirtide